Get the Stockscreener App
8.1129
3.64%
-0.3171
Cervomed Inc stock is traded at $8.1129, with a volume of 57,945.
It is down -3.64% in the last 24 hours and up +18.59% over the past month.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
See More
Previous Close:
$8.43
Open:
$8.46
24h Volume:
57,945
Relative Volume:
0.27
Market Cap:
$70.86M
Revenue:
-
Net Income/Loss:
$-6.42M
P/E Ratio:
-1.4484
EPS:
-5.6013
Net Cash Flow:
$-7.45M
1W Performance:
+12.51%
1M Performance:
+18.59%
6M Performance:
+272.62%
1Y Performance:
-46.98%
1-Day Range:
$8.05
$8.46
1-Week Range:
$7.09
$8.6279
52-Week Range:
$1.80
$20.63
Cervomed Inc Stock (CRVO) Company Profile
Name
Cervomed Inc
Sector
Industry
Phone
(617) 744-4400
Address
20 PARK PLAZA, BOSTON
Compare CRVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRVO
Cervomed Inc
|
8.1418 | 61.88M | 0 | -6.42M | -7.45M | -5.6013 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.33 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.14 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.73 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.59 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
293.86 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Dec-17-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-11-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Dec-11-24 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Dec-10-24 | Downgrade | D. Boral Capital | Buy → Hold |
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Dec-05-24 | Initiated | H.C. Wainwright | Buy |
| Sep-18-24 | Initiated | Chardan Capital Markets | Buy |
| Jul-26-24 | Initiated | Morgan Stanley | Overweight |
| Feb-15-24 | Initiated | Canaccord Genuity | Buy |
| Nov-17-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-21-18 | Initiated | H.C. Wainwright | Buy |
View All
Cervomed Inc Stock (CRVO) Latest News
What analysts say about CervoMed Inc. stockFree Stock Market Forecast Reports - jammulinksnews.com
Is CervoMed Inc. a good long term investmentHigh-yield growth strategies - jammulinksnews.com
What drives CervoMed Inc. stock priceConsistently high returns - jammulinksnews.com
CervoMed Inc. Stock Analysis and ForecastUnstoppable investment returns - jammulinksnews.com
CervoMed’s Dementia Drug Saga Tests Investor Patience And Nerves - Finimize
How CervoMed Inc. stock performs during market volatilityStrategic High Profit Opportunities - Newser
Why CervoMed Inc. stock attracts strong analyst attentionTrend Based Entry Alerts - Newser
What makes CervoMed Inc. stock price move sharplyFree Stock Selection with 300% Return - Newser
Brokerages Set CervoMed Inc. (NASDAQ:CRVO) Price Target at $22.57 - Defense World
CervoMed Strengthens Leadership with Technical Operations Hire to Advance Neflamapimod Toward Phase 3 - MSN
CervoMed Inc. to Present Late-Breaking Data on Neflamapimod at Alzheimer’s Association International Congress 2025 - Nasdaq
CervoMed Announces Late-Breaking Presentations at Alzheimer’s Association® International Congress 2025 - GlobeNewswire
Late-Breaking Phase 2b Results: CervoMed's Novel DLB Drug Shows Effects on Clinical Progression - Stock Titan
CervoMed Inc.(NasdaqCM: CRVO) dropped from Russell 2000 Dynamic Index - MarketScreener
CervoMed Inc.(NasdaqCM: CRVO) dropped from Russell 3000E Index - MarketScreener
CervoMed Inc.(NasdaqCM: CRVO) dropped from Russell 2000 Index - MarketScreener
CervoMed Inc. (NASDAQ:CRVO) Shares Bought by Rhumbline Advisers - Defense World
CervoMed Stockholders Approve Key Proposals at Annual Meeting - TipRanks
CervoMed Inc. (NASDAQ:CRVO) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
CervoMed’s (CRVO) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
CervoMed (CRVO) Receives Continued 'Buy' Rating with Target Pric - GuruFocus
CervoMed (CRVO) Receives Continued 'Buy' Rating with Target Price Held Steady | CRVO Stock News - GuruFocus
CervoMed (CRVO) Strengthens Leadership with Key Executive Appoin - GuruFocus
CervoMed (CRVO) Strengthens Leadership with Key Executive Appointment | CRVO Stock News - GuruFocus
CervoMed appoints Marco Verwijs as EVP, technical operations - TipRanks
CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization - GlobeNewswire
CervoMed Accelerates Phase 3 DLB Drug Development With Key Manufacturing Expert Hire - Stock Titan
CRVOCervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates - mx.advfn.com
Nuveen Asset Management LLC Acquires 22,104 Shares of CervoMed Inc. (NASDAQ:CRVO) - Defense World
BNP Paribas Financial Markets Purchases New Position in CervoMed Inc. (NASDAQ:CRVO) - Defense World
Reviewing CervoMed (CRVO) and Its Peers - Defense World
CervoMed Inc. (NASDAQ:CRVO) Given Average Rating of “Moderate Buy” by Analysts - Defense World
CervoMed Releases New Business and Financial Information - TipRanks
Pre-market Movers: CMRX, CPIX, PBM, CRVO... - RTTNews
Chardan Capital Raises Earnings Estimates for CervoMed - Defense World
Roth Capital Brokers Reduce Earnings Estimates for CervoMed - Defense World
Brokers Set Expectations for CervoMed Q2 Earnings - Defense World
Insider Buying: William Elder Acquires Additional Shares of Cerv - GuruFocus
CervoMed (NASDAQ:CRVO) Earns “Buy” Rating from D. Boral Capital - Defense World
CervoMed Inc. (CRVO) Reports Q1 Loss, Tops Revenue Estimates - MSN
Cervomed Inc Stock (CRVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cervomed Inc Stock (CRVO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ELDER WILLIAM ROBERT | CFO & GC |
Aug 27 '24 |
Buy |
18.16 |
1,000 |
18,160 |
1,267 |
0.53%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):